System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD262 / TRAIL-R2

DR5-01-1 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-461-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-461-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-461-C025 FITC 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1F-461-C100 FITC 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-461-C025 PE 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1P-461-C100 PE 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

Specificity

The antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).

Regulatory Status

Immunogen

Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
    Recommended dilution: 1-10 μg/ml
    Positive control: JURKAT human peripheral blood leukemia T cell line
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Corallini F, Milani D, Nicolin V, Secchiero P: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leuk Lymphoma. 2006 Aug;47(8):1459-68. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG1 Isotype Control
  • Recombinant human TRAIL-R2 (DR5/ TNFRSF10B)/Fc Chimera
  • Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy